Terms: = Prostate cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB
66 results:
1. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway.
Zhang X; Li H; Wang Y; Zhao H; Wang Z; Chan FL
Cell Death Dis; 2024 Mar; 15(3):234. PubMed ID: 38531859
[TBL] [Abstract] [Full Text] [Related]
2. A plasma membrane-associated form of the androgen receptor enhances nuclear androgen signaling in osteoblasts and prostate cancer cells.
Kalyanaraman H; Casteel DE; China SP; Zhuang S; Boss GR; Pilz RB
Sci Signal; 2024 Jan; 17(821):eadi7861. PubMed ID: 38289986
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and ctnnb1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
[TBL] [Abstract] [Full Text] [Related]
5. Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis.
Ding D; Blee AM; Zhang J; Pan Y; Becker NA; Maher LJ; Jimenez R; Wang L; Huang H
Nat Commun; 2023 Aug; 14(1):4671. PubMed ID: 37537199
[TBL] [Abstract] [Full Text] [Related]
6. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract] [Full Text] [Related]
7. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on ctnnb1 mRNA.
Zhang S; Lv C; Niu Y; Li C; Li X; Shang Y; Zhang Y; Zhang Y; Zhang Y; Zeng Y
Cell Death Dis; 2023 Feb; 14(2):91. PubMed ID: 36750551
[TBL] [Abstract] [Full Text] [Related]
8. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive prostate cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract] [Full Text] [Related]
9. SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses prostate cancer Growth and Migration.
Eguchi T; Csizmadia E; Kawai H; Sheta M; Yoshida K; Prince TL; Wegiel B; Calderwood SK
Cells; 2022 Dec; 11(24):. PubMed ID: 36552758
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced prostate cancer: Differences in Genomic Landscape Based on Race.
Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J; Mack A; Ravindranathan D; Maughan BL; Nussenzveig R; Yandell M; Kohli M; Lilly MB; Sartor AO; Agarwal N; Barata PC
Oncologist; 2022 Oct; 27(10):e815-e818. PubMed ID: 36036607
[TBL] [Abstract] [Full Text] [Related]
11. Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.
Werner TV; Kock S; Weber I; Kayser G; Werner M; Lassmann S
J Mol Diagn; 2022 Jul; 24(7):784-802. PubMed ID: 35787794
[TBL] [Abstract] [Full Text] [Related]
12. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract] [Full Text] [Related]
13. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant prostate cancer.
Ma F; Arai S; Wang K; Calagua C; Yuan AR; Poluben L; Gu Z; Russo JW; Einstein DJ; Ye H; He MX; Liu Y; Van Allen E; Sowalsky AG; Bhasin MK; Yuan X; Balk SP
Cancer Res; 2022 Apr; 82(8):1518-1533. PubMed ID: 35131873
[TBL] [Abstract] [Full Text] [Related]
14. High expression of NPM1 via the Wnt/β-catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma.
Ruan Y; Xu H; Ji X
Clin Exp Pharmacol Physiol; 2022 Apr; 49(4):525-535. PubMed ID: 35108408
[TBL] [Abstract] [Full Text] [Related]
15. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
Lindh C; Samaratunga H; Delahunt B; Bergström R; Chellappa V; Yaxley J; Lindberg J; Egevad L
Prostate; 2022 Apr; 82(5):576-583. PubMed ID: 35049068
[TBL] [Abstract] [Full Text] [Related]
16. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive prostate cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract] [Full Text] [Related]
17. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract] [Full Text] [Related]
18. In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with prostate cancer progression.
Singh AN; Sharma N
Andrologia; 2021 Dec; 53(11):e14236. PubMed ID: 34468989
[TBL] [Abstract] [Full Text] [Related]
19. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.
Luo Y; Vlaeminck-Guillem V; Baron S; Dallel S; Zhang CX; Le Romancer M
J Exp Clin Cancer Res; 2021 Aug; 40(1):270. PubMed ID: 34446068
[TBL] [Abstract] [Full Text] [Related]
20. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract] [Full Text] [Related]
[Next]